|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We developed a novel algorithm for assessing the complementarity of tumor mutant peptides and TCR CDR3s, based on the retrieval of TCR CDR3 AA sequences from both tumor specimen and patient blood exomes and by using an automated process of assessing CDR3 and mutant AA electrical charges.
|
31821535 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Analysis of amino-acid sequence similarities revealed a significant increase in the number and richness of dominant CDR3 motifs in tumors treated with RT + anti-CTLA-4 compared with control.
|
29180535 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our research suggests that the TCR γδ CDR3 repertoire changed in LC patients due to the antitumor immune response by γδ T cells in vivo, and these changes primarily focus on the amplification of certain tumor-specific CDR3δ clones among patients.
|
29400706 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In a recent manuscript by Sheikh and colleagues, the investigators evaluated changes in T cell clonality in the peripheral blood and tumors of patients treated with sipuleucel-T using next generation sequencing of T cell receptor Vß CDR3 sequences.
|
27879971 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In 1,078 TCGA breast cancer exomes, the fraction of CDR3 reads was associated with TILs fraction, tumor purity, adaptive immunity gene expression signatures and improved survival in Her2+ patients.
|
27452728 |
2016 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The clonal relationship is confirmed by identical CDR3 length and single nucleotide polymorphisms as well as a matching IgH sequence of the cell line and founding tumor.
|
22812491 |
2013 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Both tumor-infiltrating Tregs and T effector cells (Teff) displayed sequence profiles in the CDR3 region that were characteristic of biased repertoires seen during clonal cell expansions, implying that strong T-cell responses have occurred within the tumor tissue.
|
22573714 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CDR3 spectratyping was feasible and highly reproducible in each tumor, and indicated a restricted repertoire for specific TCR Vβ chains in tumor-infiltrating T cells.
|
21785264 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We identified two substitutions in the CDR3 of the alpha chain that significantly influenced tumor cell recognition by human peripheral blood lymphocytes.
|
19118044 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To elucidate key structural basis of the specificity of gammadelta TCR for tumors, we analyzed the binding activities of synthesized TCR Vdelta2 CDR3 peptides derived from tumor infiltrating lymphocyte (TIL) s in ovarian epithelial carcinoma (OEC) via biospecific interaction analysis approach, enzyme immunoassay and immunofluorescence assays.
|
16650897 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Clonotypic PCR using CDR3-specific primers was applied to the tumor tissue containing the tumor-infiltrating lymphocytes.
|
15067062 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Similar peak patterns of CDR3 size spectratyping were observed among these tumor specimens, but not in normal tissues or PBMCs.
|
15201998 |
2004 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The tumor-specific V(H) CDR3 nucleotide sequence was successfully identified for all seven patients (3 mature B-ALL and BL).
|
14565664 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition to this, the T cells isolated from the sites of the tumor cells from four of these five patients also demonstrated significant increase in the number of TCR Vbeta gene families with restricted number of CDR3 size peaks and loss of the normal CDR3 size gaussian distribution pattern.
|
11251941 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data indicate: 1) NMZL is derived from B cells that have experienced the germinal center reaction; 2) the preferential usage of a VH1-69 segment in the majority of the HCV-positive NMZL cases with similar CDR3s suggests the presence of a common antigen, probably a HCV antigen epitope, involved in the B-cell selection; and 3) the use of a VH4-34 segment suggests a role of yet unknown B-cell superantigen(s) in the selection of tumor B-cell precursors in HCV-negative NMZL.
|
11438472 |
2001 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Sequencing of the CDR3 region revealed unique VH-N-D and D-N-JH junctions, thus corroborating the presence of two genuinely distinct tumor clones in each of these three cases.
|
11454985 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CDR III IgH PCR has been confirmed as an efficient method for determining clonality in B-cell neoplasias.
|
10975394 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
For this purpose, we have used a high-resolution PCR-based method that determines CDR3 size patterns in TCRVbeta sub-families in fresh tumors and their corresponding autologous PBL samples.
|
10188720 |
1999 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In one patient a single clonally expanded SLSGTGVNEQF CDR3 clonotype accounted for the entire BV14 relative frequency of expression (24%) in tumor-infiltrating lymphocytes (TIL).
|
10235487 |
1999 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The VH genes of one tumour displayed three populations with varying CDR3 length at diagnosis.
|
10583269 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CDR3 sequences obtained from one patient revealed an in situ expansion of two clones in the amygdala (one at a frequency of 57%) and four clones in the tumor.
|
9781545 |
1998 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
PCR findings obtained with the optimized IgH-CDR3-PCR assay showed an overall monoclonality detection rate of 97% (97 of 101 cases with B cell neoplasms).
|
9204991 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CDR3 spectratying of the RT-PCR products demonstrated the precise clonal nature of the tumour and non-tumour tissue showing that the non-tumour tissue comprised an oligoclonal population of a number of different T cell receptor V beta families.
|
9462260 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
3) qPCR results with plasmids carrying CDR3 regions simulating different tumor loads diverged by no more than a factor of 1.6 from the expected values.
|
9296214 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data indicated that functional cytotoxic T cells with these distinct CDR3 equivalent structures were the dominant effector cells against HST2 autologous tumor cells.
|
8671591 |
1996 |